Collectively, the results are consistent with a model where immunotherapy can generate a sufficient CD8+ T cell response throughout the 12-day timeframe to control tumor growth that initially coincides with an increase in antigen presentation by tumor cells. This evidence concerns the gene CD8A and neoplasm.